loading
전일 마감가:
$2.49
열려 있는:
$2.48
하루 거래량:
63,814
Relative Volume:
0.20
시가총액:
$58.29M
수익:
-
순이익/손실:
$-94.11M
주가수익비율:
-0.4218
EPS:
-6.01
순현금흐름:
$-86.06M
1주 성능:
+12.44%
1개월 성능:
+11.45%
6개월 성능:
-47.29%
1년 성능:
-63.75%
1일 변동 폭
Value
$2.4163
$2.54
1주일 범위
Value
$2.14
$2.598
52주 변동 폭
Value
$1.78
$10.14

Adverum Biotechnologies Inc Stock (ADVM) Company Profile

Name
명칭
Adverum Biotechnologies Inc
Name
전화
(650) 649-1004
Name
주소
100 CARDINAL WAY, REDWOOD CITY, CA
Name
직원
155
Name
트위터
@adverumbio
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
ADVM's Discussions on Twitter

ADVM을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ADVM
Adverum Biotechnologies Inc
2.53 58.29M 0 -94.11M -86.06M -6.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.43 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
523.86 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.50 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
561.27 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.30 28.51B 3.81B -644.79M -669.77M -6.24

Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-06-25 개시 Oppenheimer Outperform
2024-04-30 개시 H.C. Wainwright Buy
2022-07-07 업그레이드 Truist Hold → Buy
2021-07-23 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2021-05-03 다운그레이드 SVB Leerink Outperform → Mkt Perform
2021-04-29 다운그레이드 Chardan Capital Markets Buy → Neutral
2021-04-29 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2021-04-29 다운그레이드 Truist Buy → Hold
2020-12-16 개시 UBS Neutral
2020-11-12 업그레이드 Raymond James Underperform → Mkt Perform
2020-06-26 다운그레이드 Raymond James Mkt Perform → Underperform
2020-05-13 개시 RBC Capital Mkts Outperform
2020-05-05 업그레이드 SunTrust Hold → Buy
2020-04-28 개시 Goldman Buy
2020-03-16 개시 SVB Leerink Outperform
2020-02-10 업그레이드 Cantor Fitzgerald Neutral → Overweight
2020-02-10 업그레이드 Chardan Capital Markets Neutral → Buy
2019-10-15 재확인 Chardan Capital Markets Neutral
2019-09-13 재확인 Chardan Capital Markets Neutral
2019-06-14 재개 Raymond James Mkt Perform
2018-11-02 다운그레이드 Raymond James Outperform → Mkt Perform
2018-11-02 다운그레이드 SunTrust Buy → Hold
2018-09-21 개시 Cantor Fitzgerald Overweight
2018-08-30 개시 SunTrust Buy
2018-02-15 재개 Piper Jaffray Overweight
2017-10-12 개시 Raymond James Outperform
모두보기

Adverum Biotechnologies Inc 주식(ADVM)의 최신 뉴스

pulisher
Jun 18, 2025

Adverum Biotechnologies shareholders approve stock option repricing - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Adverum Biotechnologies shareholders approve stock option repricing By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 13, 2025

Adverum Biotechnologies’ SWOT analysis: gene therapy stock faces pivotal year - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 06, 2025

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

Adverum Biotechnologies (NASDAQ:ADVM) versus Metagenomi (NASDAQ:MGX) Head-To-Head Analysis - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Adverum Awards 14,610 Shares in Stock Options and RSUs to Key New Hires - Stock Titan

Jun 05, 2025
pulisher
May 16, 2025

Adverum Biotechnologies Reports Q1 2025 Financial Results - TipRanks

May 16, 2025
pulisher
May 15, 2025

Adverum Biotechnologies (ADVM) Sees Price Target Adjustment by RBC Capital | ADVM Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Adverum Biotechnologies (ADVM) Receives Continued Buy Rating from Chardan Capital | ADVM Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Adverum Biotechnologies (ADVM) Price Target Reduced by RBC Capit - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Adverum Biotechnologies (ADVM) Rating Reiterated at 'Buy' by HC Wainwright | ADVM Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Adverum Biotechnologies: Q1 Earnings Snapshot - CT Insider

May 15, 2025
pulisher
May 14, 2025

Adverum (ADVM) Projects Funding Through Late 2025 | ADVM Stock N - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline ... - Bluefield Daily Telegraph

May 14, 2025
pulisher
May 14, 2025

Revolutionary One-Time Gene Therapy Shows 3.5-Year Vision Protection in Wet AMD Patients - Stock Titan

May 14, 2025
pulisher
May 07, 2025

Adverum Biotechnologies Inc (ADVM)’s Market Momentum: Closing Strong at 3.23, Down -10.03 - DWinneX

May 07, 2025
pulisher
May 07, 2025

Adverum Biotechnologies’ SWOT analysis: gene therapy firm faces pivotal year - Investing.com Nigeria

May 07, 2025
pulisher
May 06, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc.ADVM - PR Newswire

May 06, 2025
pulisher
May 06, 2025

Adverum Biotechnologies' SWOT analysis: gene therapy firm faces pivotal year - Investing.com

May 06, 2025
pulisher
May 05, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum ... - Bluefield Daily Telegraph

May 05, 2025
pulisher
May 05, 2025

Adverum Biotechnologies Inc expected to post a loss of $1.94 a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 02, 2025

Adverum Biotechnologies Awards Strategic Stock Options Worth $108,000 to Expand Team - Stock Titan

May 02, 2025
pulisher
May 02, 2025

It makes sense and dollars to buy Adverum Biotechnologies Inc (ADVM) stock - Sete News

May 02, 2025
pulisher
Apr 30, 2025

Adverum Biotechnologies Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com

Apr 30, 2025
pulisher
Apr 28, 2025

Adverum Biotechnologies Inc [ADVM] Investment Guide: What You Need to Know - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

Should investors be concerned about Adverum Biotechnologies Inc (ADVM)? - uspostnews.com

Apr 28, 2025
pulisher
Apr 28, 2025

Gaining Ground: Adverum Biotechnologies Inc (ADVM) Closes Lower at 2.91, Down -2.02 - DWinneX

Apr 28, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 24, 2025

Hedge Fund and Insider Trading News: Ken Griffin, Steve Cohen, Scott Bessent, Balyasny Asset Management, Bridgewater Associates, Starboard Value, Maverick Capital, Kodai Capital Management, Antara Capital, Adverum Biotechnologies Inc (ADVM), and - Insider Monkey

Apr 24, 2025
pulisher
Apr 24, 2025

Adverum Biotechnologies Insider Bought Shares Worth $1,048,950, According to a Recent SEC Filing - marketscreener.com

Apr 24, 2025
pulisher
Apr 24, 2025

Adverum Biotechnologies Insider Buys 350,000 Shares - TradingView

Apr 24, 2025
pulisher
Apr 23, 2025

Adverum Biotechnologies Inc (ADVM) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Trading Day Triumph: Adverum Biotechnologies Inc (ADVM) Ends at 2.96, a 8.42 Surge/Plunge - DWinneX

Apr 23, 2025
pulisher
Apr 21, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com

Apr 21, 2025
pulisher
Apr 21, 2025

Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating - marketscreener.com

Apr 21, 2025
pulisher
Apr 20, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation - markets.businessinsider.com

Apr 20, 2025
pulisher
Apr 18, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out - markets.businessinsider.com

Apr 18, 2025
pulisher
Apr 18, 2025

Adverum Biotechnologies (NASDAQ:ADVM) Earns Buy Rating from HC Wainwright - Defense World

Apr 18, 2025
pulisher
Apr 17, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out - markets.businessinsider.com

Apr 17, 2025
pulisher
Apr 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - GlobeNewswire Inc.

Apr 17, 2025

Adverum Biotechnologies Inc (ADVM) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Adverum Biotechnologies Inc 주식 (ADVM) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Seyedkazemi Setareh
CHIEF DEVELOPMENT OFFICER
May 15 '25
Sale
2.00
924
1,848
13,768
Fischer Laurent
CEO, PRESIDENT AND DIRECTOR
May 15 '25
Sale
2.00
9,126
18,252
87,488
Leonard Braden Michael
10% Owner
Mar 26 '25
Buy
5.04
20,407
102,841
125,207
Leonard Braden Michael
10% Owner
Mar 27 '25
Buy
5.19
16,593
86,089
141,800
Leonard Braden Michael
10% Owner
Apr 22 '25
Buy
3.00
300,000
900,000
3,057,526
Leonard Braden Michael
10% Owner
Apr 23 '25
Buy
2.98
50,000
148,950
191,800
Leonard Braden Michael
10% Owner
Mar 31 '25
Buy
4.38
19,566
85,668
2,742,317
Leonard Braden Michael
10% Owner
Apr 02 '25
Buy
4.04
15,209
61,408
2,757,526
Leonard Braden Michael
10% Owner
Mar 26 '25
Buy
5.04
20,407
102,841
125,207
Leonard Braden Michael
10% Owner
Mar 18 '25
Buy
4.69
62,341
292,418
2,667,161
$20.42
price down icon 1.37%
$35.45
price up icon 0.65%
$21.06
price down icon 1.92%
$101.83
price down icon 0.41%
$105.86
price down icon 0.39%
biotechnology ONC
$244.00
price down icon 3.69%
자본화:     |  볼륨(24시간):